Josh Disbrow, Aytu BioScience's Chief Executive Officer...

Josh Disbrow, Aytu BioScience's Chief Executive Officer commented, ''We are pleased to be partnering with SUDA as they develop ZolpiMist commercial opportunities around the world. In a short period of time the SUDA team has entered into several sublicensing arrangements with prominent pharmaceutical companies. As such, we expect to see regulatory clearance in at least one market in the coming year. We thank CEO Stephen Carter and the SUDA team for their partnership and look forward to working with SUDA as they continue their ongoing commercial efforts with ZolpiMist around the world.''

Stephen Carter, SUDA Pharmaceuticals' Chairman and Chief Executive Officer added, ''SUDA is pleased to continue its ZolpiMist program with Aytu. We have a number of discussions in place to further the global footprint of the ZolpiMist brand. We are looking forward to the ongoing achievement of commercial milestones and the continued roll out of regulatory submissions with our partners.''

https://www.marketwatch.com/press-r...greement-with-suda-pharmaceuticals-2019-03-06